Regencell Bioscience(US:RGC) 投中网·2025-06-19 03:34Core Viewpoint - The article discusses the remarkable stock performance of Regencell, a Chinese company listed in the US, which has seen its stock price increase by 600 times in 2025, reaching a market capitalization of over $38.5 billion (approximately 270 billion RMB) [4][5]. Company Overview - Regencell is an early-stage Chinese medicine biotechnology company focused on developing standardized liquid herbal formulas for treating ADHD and ASD patients [5]. - The company was founded in 2014 in Hong Kong and currently operates with a small team of only 12 employees [5]. - Despite its soaring stock price, Regencell has reported zero revenue since its inception and has been operating at a loss, with net losses of $6.062 million and $4.363 million for the fiscal years 2023 and 2024, respectively [5][10]. Stock Performance - Regencell's stock price surged dramatically, with a notable increase of 283% on June 16, 2025, and a pre-market rise of 64% the following day, reaching a closing price of $78 [4]. - The company's market capitalization is compared to major Chinese companies, being about 10% of Alibaba's market cap and 90% of Pop Mart's [4]. - The stock's liquidity was previously low, with only 11.2% of shares in circulation, prompting a stock split to enhance liquidity [4]. Founder Background - The founder, Regencell's CEO, graduated from UC Berkeley and has a background in investment banking, having completed over $4 billion in transactions [7]. - The founder's personal experience with ADHD and ASD, along with the influence of his father's traditional Chinese medicine practice, inspired the establishment of Regencell [8]. Market Dynamics - The surge in Regencell's stock price is attributed to the broader excitement around brain-computer interface (BCI) technologies, rather than its core business in traditional Chinese medicine [10][11]. - Recent advancements in BCI technology, including FDA-approved clinical trials for a new neural modulation chip, have fueled investor interest in related stocks [11][12]. - The article notes that the stock's performance appears disconnected from the company's actual business fundamentals, highlighting a speculative trend in the market [13].